Hemorai

Executive Summary

Hemorai is an early-stage US digital health company developing AI-powered software for automated analysis of blood smear images, targeting improvements in hematology diagnostics. Founded in 2018 and headquartered in San Francisco, the company operates at the intersection of hematology, digital pathology, and machine learning. Its technology aims to provide rapid, standardized, and quantitative assessments of blood samples, potentially reducing manual workload for laboratory professionals and enhancing diagnostic accuracy. While Hemorai has not disclosed funding or commercial product status, its focus on AI-driven hematology aligns with growing demand for automation in clinical laboratories. The company faces competition from established players and emerging startups, but its specialized AI approach could differentiate it if regulatory and clinical validation are achieved. Key near-term catalysts include regulatory clearance (e.g., FDA 510(k)), partnerships with reference laboratories, and publication of clinical validation studies. Hemorai's success will depend on demonstrating clinical utility, securing reimbursement, and scaling adoption in a conservative healthcare market.

Upcoming Catalysts (preview)

• Q3 2026FDA 510(k) Clearance for AI Blood Smear Analysis Software60% success
• Q3 2026Commercial Partnership with Major Reference Laboratory50% success
• Q3 2026Publication of Clinical Validation Study Results70% success